deCODE genetics announced financial results for the second quarter 2005 yesterday, posting a net loss of USD 13.3 million. Net loss for the first six months was USD 30.3 million compared with a net loss of USD 25.3 million for the first half of 2004. Morgunbladid points out that net loss increased almost 20% year-over-year.
In a released statement deCODE cite the loss the result of increased spending on it’s drug development programs.
Revenue was USD 21 million in the first half of 2005 compared with revenue of USD 19.9 million for the same period 2004, an increase of 5%.
In an interview with Morgunbladid last month deCODE CEO Kári Stefánsson said, “We have held our own and never performed better.”
